Filtered By:
Education: Grants
Countries: USA Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 84 results found since Jan 2013.

Extreme Heat Is Endangering America ’ s Workers —And Its Economy
This project was supported by the Pulitzer Center 7 A.M.: COPELAND FARMS—ROCHELLE, GA Just after dawn on a recent July day in Rochelle, Ga., Silvia Moreno Ayala steps into a pair of sturdy work pants, slips on a long-sleeved shirt, and slathers her face and hands with sunscreen. She drapes a flowered scarf over her wide-brimmed hat to protect her neck and back from the punishing rays of the sun. There isn’t much she can do about the humidity, however. Morning is supposed to be the coolest part of the day, but sweat is already pooling in her rubber boots. [time-brightcove not-tgx=”true”] ...
Source: TIME: Health - August 3, 2023 Category: Consumer Health News Authors: Aryn Baker / Georgia Tags: Uncategorized climate change Climate Is Everything feature healthscienceclimate Source Type: news

Will unpredictable side effects dim the promise of new Alzheimer ’s drugs?
A sea change is underway in the treatment of Alzheimer’s disease, where for the first time a drug that targets the disease’s pathology and clearly slows cognitive decline has hit the U.S. market. A related therapy will likely be approved in the coming months. As many neurologists, patients, and brain scientists celebrate, they’re also nervously eyeing complications from treatment: brain swelling and bleeding, which in clinical trials affected up to about one-third of patients and ranged from asymptomatic to fatal. The side effect—amyloid-related imaging abnormalities, or ARIA—remains mysterious. “We don’...
Source: Science of Aging Knowledge Environment - August 2, 2023 Category: Geriatrics Source Type: research

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen ’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations
TITUSVILLE, NJ, November 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first impact summary for its Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now multi-year initiative, designed to create urgency and action around the hidden threat of peripheral artery disease (PAD)-related amputation. In its inaugural year, Save Legs. Change Lives.™ focused on reaching Black Americans, who are up to four times more likely than white Americans to have a PAD-related amputation.1 With this critical initiative, Janssen is focused on helping those at risk of PAD through more th...
Source: Johnson and Johnson - November 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Deep brain stimulation for movement disorders after stroke: a systematic review of the literature
CONCLUSIONS: This is the first systematic review of DBS for poststroke movement disorders. Overall, most studies to date have been case reports and small series reporting heterogeneous patients and surgical strategies. This review suggests that DBS for movement disorders after a stroke has the potential to be effective and safe for diverse patients, and DBS may be a feasible option to improve function even years after a stroke.PMID:36308482 | DOI:10.3171/2022.8.JNS221334
Source: Journal of Neurosurgery - October 29, 2022 Category: Neurosurgery Authors: Mitch R Paro Michal Dyrda Srinath Ramanan Grant Wadman Stacey-Ann Burke Isabella Cipollone Cory Bosworth Sarah Zurek Patrick B Senatus Source Type: research

Feasibility of Sentinel Cerebral Embolic Protection Device Deployment During Transfemoral Transcatheter Aortic Valve Replacement
Cerebral embolic protection has emerged as a preventive measure for procedural stroke in transcatheter aortic valve replacement (TAVR).1 The Sentinel System (Boston Scientific Corp. Boston, Massachusetts), a 2-filter debris-capturing system, has been the only commercially available protection device in the United States since its approval by the Food and Drug Administration in 2017. In the Sentinel trial, the largest randomized trial (n  = 363) so far, the device was successfully deployed in 94.7% of patients.
Source: The American Journal of Cardiology - October 1, 2022 Category: Cardiology Authors: Toshiaki Isogai, Husitha Reddy Vanguru, Amar Krishnaswamy, Ankit Agrawal, Nikolaos Spilias, Shashank Shekhar, Anas M. Saad, Beni Rai Verma, Rishi Puri, Grant W. Reed, Zoran B. Popovi ć, Shinya Unai, James J. Yun, Ken Uchino, Samir R. Kapadia Source Type: research

O-007 First US multicenter experience using the pipeline flex embolization device with shield technology for treatment of intracranial aneurysms - periprocedural outcomes and early safety profile
ConclusionOur study is the first to report the early experience with the newly FDA-approved PED Flex with Shield technology amongst US centers. Our results are comparable with non-US, international studies showing a high technical success rate and safe peri-procedural angiographic and patient outcome. Long-term follow-up will be needed to provide more robust data on angiographic and patient outcomes.Disclosures A. Kuhn: None. J. Singh: None. A. Abdelsalam: None. V. Saini: None. J. Burks: None. G. Cortez: None. R. Abbas: None. M. Pervez: None. H. Saei: None. S. Burke: None. V. Naragum: None. F. Massari: None. S. Marwah: Non...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Kuhn, A., Singh, J., Abdelsalam, A., Saini, V., Burks, J., Cortez, G., Abbas, R., Pervez, M., Saei, H., Burke, S., Naragum, V., Massari, F., Marwah, S., Gounis, M., Hassan, A., Malek, A., Dabus, G., Linfante, I., Tjoumakaris, S., Jabbour, P., Hanel, R., S Tags: SNIS 19th annual meeting oral abstracts Source Type: research

E-182 A multicentric experience for the use of flow diverter in the treatment of anterior communicating artery aneurysms
ConclusionFlow diverters appear to be a safe and effective treatment for anterior communicating artery aneurysms, presenting as an alternative strategy in the armamentarium of interventionalist. Mid-term results were favorable, and complication rates were low. Additional studies with longer follow-up time and independent adjudication are warranted to confirm the safety and effectiveness of the technique.Disclosures V. Benalia: None. G. Cortez: None. N. Kocer: None. C. Islak: None. I. Saatci: None. S. Cekirge: None. F. Baltacıoğlu: None. G. Dabus: None. C. Mounayer: None. A. Siddiqui: None. D. Lopes: None. W. ...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Benalia, V., Cortez, G., Kocer, N., Islak, C., Saatci, I., Cekirge, S., Baltacıoglu, F., Dabus, G., Mounayer, C., Siddiqui, A., Lopes, D., Brinjikji, W., Aghaebrahim, A., Sauvageau, E., Hanel, R. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

P-013 Designing and prototyping a novel balloon-stent device for minimally invasive temporary aneurysm occlusion and embolization
ConclusionA balloon-stent device allows for longer neuro-interventional procedures by providing continuous perfusion without arresting blood flow during balloon inflation. In addition, this novel medical device provides a smooth surface at the aneurysm neck for consistent device placement, minimization of parent vessel trauma, elimination of ischemic effects distal to the parent artery, and minimization of intra-saccular flow remnants pre- and post-treatment.Abstract P-013 Figure 1a) FPR results from theoretical estimation, benchtop modeling, and computational fluid dynamic (CFD) simulation. B) balloon component of the bal...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Asgari, O., Fennell, B., Norris, N., Ducruet, A., Becker, T. Tags: SNIS 19th annual meeting oral poster abstracts Source Type: research

Impact of Hospital Volume on Utilization and Outcomes of Sentinel Cerebral Protection System During Transcatheter Aortic Valve Implantation
Stroke remains a serious complication of transcatheter aortic valve implantation (TAVI) with a significant impact on long-term morbidity and mortality. Although the etiology of strokes is multifactorial, most are a result of embolization of debris during the procedure.1 Multiple devices have emerged aiming to reduce the incidence of stroke through cerebral embolic protection. The Sentinel cerebral protection system (CPS) is the only Food and Drug Administration-approved device in the United States.
Source: The American Journal of Cardiology - July 13, 2022 Category: Cardiology Authors: Agam Bansal, Toshiaki Isogai, Mohamed M. Gad, Grant W. Reed, Rishi Puri, Amar Krishnaswamy, Samir R. Kapadia Source Type: research